期刊文献+

唑来膦酸对鼠骨质疏松性骨折愈合及TGF-β表达影响的实验研究 被引量:1

Effects of zoledronic acid on TGF-β expression during bone fracture healing in osteoporotic rats
在线阅读 下载PDF
导出
摘要 目的研究唑来膦酸对去势大鼠骨质疏松性骨折愈合及转化生长因子(TGF-β)表达的影响。方法 60只6月龄雌性SD大鼠建立骨质疏松性骨折模型后,将其随机分为实验组和对照组,分别给予唑来膦酸、生理盐水皮下注射。两组于术后不同时间段取骨痂行苏木素-伊红(HE)染色,测骨密度、免疫组化及X线片观察骨折愈合情况。结果实验组比同期对照组骨痂生成量多、愈合时间提前、骨折局部骨密度明显增高,差异有统计学意义(P<0.05)。TGF-β于4周左右表达达到高峰,实验组比对照组TGF-β表达更明显(P<0.05)。结论唑来膦酸能加快骨痂形成,促进成骨细胞TGF-β的表达,促进骨质疏松性骨折的愈合。 Objective To research the effects of zoledronic acid on healing of osteoporotic fractures and expression of TGF-β in rats. Methods Sixty 6-month-old female SD rats of osteoporotic fracture model were randomly divided into control group and experimental group, and were given saline injection or zoledronic acid respectively. The callus formation was assessed with HE-stained histology; The healing of osteoporotic fractures was assessed by TGF-β immunohistochemistry (IHC), bone mineral density (BMD) and X-ray. Results Compared with the concurrent control group, the experimental group had more callus formation, more advanced healing time, markedly higher bone mineral density in fracture region, and the differences were statistically significant (P 〈 0.05). TGF-β expression reached its peak at about four weeks, and TGF-β expression of the experimental group was more than that of the control group (P 〈 0.05). Conclusion Zoledronic acid can stimulate the growth of bone, promote the healing of osteoporotic fracture through promoting expression of TGF-β in ovariectomized rats.
出处 《中国现代医生》 2012年第9期13-14,17,共3页 China Modern Doctor
关键词 唑来膦酸 转化生长因子-Β 骨质疏松 骨折 Zoledronic acid TGF-β Osteoporosis Fracture
  • 相关文献

参考文献8

  • 1Plotkin LI,Weinstein RS,Parfitt AM,et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin[J]. J Clin Invest, 1999,104(10) : 1363-1374.
  • 2荆波,尹芸生,张涛,王兴宇,郑振雨,陈晓敏,闻伟敬.唑来膦酸对大鼠成骨细胞护骨素及肿瘤坏死因子αmRNA表达的影响[J].中国组织工程研究与临床康复,2011,15(2):277-280. 被引量:2
  • 3郑振雨,荆波,尹芸生.唑来膦酸对成骨细胞增殖及IGF-1表达的影响[J].中国医药导报,2010,7(35):20-21. 被引量:4
  • 4Black DM,Delmas PD,Easte11 R,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med ,2007,356(18):1809-1822.
  • 5Delmas PD,Munoz F,Black DM,et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduc tion in postmenopausal women with osteoporosis[J]. J Bone Miner Res, 2009,24(9) : 1544-1551.
  • 6Eastell R,Black DM,Boonen S,et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density[J]. J Clin Endocrinol Metab, 2009,94 (9) : 3215-3225.
  • 7Boonen S,Black DM,Col6n-Emeric CS,et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older[J]. J Am Geriatr Soc, 2010,58 (2) : 292-299.
  • 8Gamsjaeger S, Buchinger B, Zwettler E, et al. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteo- porosis after three years of treatment with once-yearly zoledronic acid[J]. J Bone Miner Res ,2011,26( 1 ) : 12-18.

二级参考文献29

  • 1苏钟毅,尹芸生,李栋,胡宏亮,刘巍,郝东升.胰岛素样生长因子-Ⅰ促骨质疏松骨折愈合的实验研究[J].中国药物与临床,2007,7(3):182-185. 被引量:14
  • 2Russell RG.Bisphosphonates:from bench to bedside[J].Ann NY Acad Sci,2006,1068:367-401.
  • 3Rogers MJ,Gordon S,Benford HI,et al.Cellular and molecular mech-anisms of action of bi sphosphonates[J].Cancer,2000,88(Suppl 12):2961-2978.
  • 4Schmid C,Guler HP,Rowe D,et al.Insulin-like growth factor 1 regulates type 1 procollagen messenger ribonucleic acid steady state levels in bone of rats[J].Endocrinology,1989,125(3):1575-1580.
  • 5Miyakoshi N,0in X,Kasukawa Y,et al.Systemic administration of insulinlike growth factor (1GF-1)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism[J].Endocrinology,2001,142(6):2641.
  • 6Hock JM,Centrells M,Canalis E,et al.Insulin-like growth factor 1 has independent effects on bone matrix formation and cell replaction[J].Endocrinology,1988,122(1):254.
  • 7Pan B,To LB,Farrugia AN,et al.The nitrogen-containing bisphosphonate,Zoledronic acid,increases mineralisation of human bone-derived cells in vitro[J].Bone,2004,34(1):112-123.
  • 8Orriss IR,Key ML,Colston KW,et al.Inhibition of osteoblast function in vitro by aminobisphosphnates[J].Journal of Cellular Biochemistry,2009,106:109-118.
  • 9Recker RR,Delmas PD,Halse J,et al.Effects of intravenous Zoledronic acid once yearly on bone remodeling and bone structure[J].J Bone Miner Res,2008,23(1):6-16.
  • 10Idres AI,Rojas J,Greig IR,et al.Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro[J].Calcif Tissue Int,2008,82(3):191-201.

共引文献4

同被引文献15

引证文献1

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部